The Ketamine StartUp Podcast

Episode 57 - Beyond the Physical: Why Treating Chronic Pain Requires Healing the Whole Person with Dr. Michelle Weiner

In this conversation, Dr. Michelle Weiner shares her evolution from chief resident in interventional pain medicine to pioneering integrative practitioner who treats chronic pain through a biopsychosocial-spiritual lens. Double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation, Dr. Weiner reveals why traditional procedure-focused approaches often fail chronic pain patients and how she discovered more effective ways to create lasting healing. Dr. Weiner's journey started with her background in nutritional science and athletics, leading her through physical medicine and rehabilitation before specializing in interventional pain. But day after day of performing procedures without truly connecting with patients left her frustrated and seeking deeper solutions. Her introduction to medical cannabis as chair of Florida's advisory committee opened her mind to personalized medicine and treating the whole person rather than just diagnosis codes. You'll hear about her unique approach to fibromyalgia, which she reframes as "central sensitization" to empower rather than limit patients. Dr. Weiner explains how trauma and adverse childhood experiences prime the nervous system for hyperreactivity, leading to chronic pain that becomes centrally mediated rather than structurally based. Her practice now integrates cannabis protocols, ketamine therapy, and comprehensive team-based care to address the root causes of both physical and emotional pain. Dr. Weiner also shares her personal ketamine experience during training, including a profound vision that later manifested in real life, demonstrating the spiritual dimension she now incorporates into treatment. You'll also hear practical insights about building an integrative practice, the importance of set and setting, and why true healing requires addressing the person with the diagnosis, not just the diagnosis itself. What You'll Learn in This Episode · Career transition insights - How Dr. Weiner evolved from high-volume interventional procedures to relationship-based integrative medicine and why she felt traditional approaches were "stringing patients along" · Central sensitization framework - Why she avoids the term "fibromyalgia" and instead explains central sensitization to empower patients and create hope rather than diagnostic limitations · Biopsychosocial-spiritual model - How incorporating the spiritual dimension creates awe-like effects and connections that traditional medicine misses, supported by neuroscience research · Medical cannabis integration - Her role on Florida's Medical Cannabis Advisory Committee and how cannabis opened conversations about personalized medicine and treating individual endocannabinoid systems · Trauma's role in chronic pain - How adverse childhood experiences and physical trauma prime the nervous system for hyperreactivity and chronic pain development · Practice building strategies - Practical advice about insurance credentialing, marketing to other providers, creating therapeutic environments, and building multidisciplinary teams · Set and setting importance - Why the physical environment, staff training, and patient preparation are crucial for maximizing ketamine therapy outcomes · Patient education approaches - How she explains that healing happens during the neuroplastic window after ketamine, not during the infusion itself, and why "more is not better" · Team-based care model - Working with coaches, therapists, and specialists trained in pain reprocessing therapy and somatic approaches to support comprehensive healing Episode 57 show notes: 00:00:00 - Teaser: Heart-Forward Medicine and True Passion  00:00:19 - Introduction and Dr. Weiner's Background Overview 00:02:00 - Educational Journey: From Nutrition Science to Pain Medicine  00:05:13 - Colleague Reactions to Non-Traditional Approach 00:08:37 - The Pivotal Moment: From Procedures to Purpose  00:11:04 - Cannabis Integration and Personalized Medicine Discovery  00:13:43 - Biopsychosocial Model and Pain Neuroscience Education  00:17:09 - Trauma Patterns and Chronic Pain Development  00:19:54 - Reframing Fibromyalgia as Central Sensitization  00:23:54 - Adding the Spiritual Dimension: Biopsychosocial-Spiritual Model  00:29:07 - Personal Ketamine Experience and Training Story  00:34:22 - Practice Building: From Employee to Business Owner  00:38:18 - Set and Setting: Creating Therapeutic Environments  00:41:48 - Patient Misconceptions and Education Strategies 00:47:08 - Rapid Fire Questions:  00:53:55 - Advice to 18-Year-Old Self 00:55:34 - Final Thoughts: Pain Complexity and Nervous System Healing  00:56:32 - Contact Information and Practice Locations  00:57:29 - Ending and Show Resources Connect with Dr. Weiner at: Website: www.drmichelleweiner.com [http://www.drmichelleweiner.com] LinkedIn: https://www.linkedin.com/in/michelle-weiner-do-mph-276b34b9 [https://www.linkedin.com/in/michelle-weiner-do-mph-276b34b9] Facebook: https://www.facebook.com/drmichelleweiner/ [https://www.facebook.com/drmichelleweiner/] 👉 Disclosure: Some of the links in these show notes are affiliate links. If you choose to make a purchase through them, we may earn a small commission at no additional cost to you. Thanks for supporting the podcast! Selected Links From the Episode: 📕The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma [https://amzn.to/4nz0qwy] by Bessel van der Kolk M.D.  [https://amzn.to/4nz0qwy] 📘The Awakened Brain: The New Science of Spirituality and Our Quest for an Inspired Life [https://amzn.to/3POPKgX] by Lisa Miller. [https://amzn.to/3POPKgX] 📝 Complete show notes with resources and  links, please visit www.ketaminestartup.com/podcast/episode-057 [http://www.ketaminestartup.com/podcast/episode-057] Follow us on LinkedIn [https://www.linkedin.com/company/ketamine-startup] Ketamine StartUp Website [https://www.ketaminestartup.com] YouTube [https://www.youtube.com/@ketaminestartup] 🚀Want to fast track launching your ketamine clinic? If so, download our free checklist [http://www.ketaminestartup.com/checklist].

Episode 56 - Breaking: Four Major Developments Reshaping Ketamine and Psychedelic Therapy

In this news roundup episode, we're covering four major developments that have emerged in recent months, all pointing toward increased accountability and oversight in the ketamine and psychedelic therapy space. This isn't our typical interview content - it's breaking news analysis that every provider in this community needs to understand. We start with the final chapter of the Matthew Perry case, where Jasveen Sangha, known as the "Ketamine Queen," received a 15-year federal prison sentence, while Dr. Salvador Plasencia was sentenced to 30 months for distributing ketamine outside proper medical supervision.  Then we cover France becoming the first country to formally authorize IV racemic ketamine for adults in severe suicidal crisis, with rigorous hospital-based protocols that raise the bar for clinical standards globally. We continue with updates on Texas Medical Board's proposed ketamine regulations moving toward mandatory clinic registration and stricter oversight, followed by analysis of President Trump's executive order accelerating psychedelic research and creating new federal pathways for investigational compounds.  We wrap up by connecting all four stories to show how legal consequences, international standards, state regulations, and federal policy are collectively signaling that oversight conversations are now happening at the highest levels of government and the field is entering a new era of accountability. What You'll Learn in This Episode · Legal accountability implications - How the Matthew Perry case sentencing creates new precedents for physician responsibility when ketamine treatment moves outside supervised clinical settings · International standards development - France's groundbreaking authorization of IV racemic ketamine for suicidal crisis and what their rigorous hospital-based protocols mean for global treatment standards · State regulatory evolution - Current status of Texas Medical Board's proposed ketamine regulations, including mandatory clinic registration and enhanced oversight requirements moving toward a June 2026 vote · Federal policy landscape changes - Analysis of Trump's executive order accelerating psychedelic research access and what new federal pathways mean for the broader psychedelic therapy field · Clinical framework implications - How France's high-surveillance psychiatric intervention model differs from wellness-oriented approaches and why this distinction matters for field credibility · Oversight trends analysis - Why legal consequences, international standards, state regulations, and federal policy are all pointing toward increased accountability requirements for providers · Risk assessment insights - Understanding where legitimate treatment can break down and how unmonitored use creates legal and ethical liability that traces back to prescribing physicians · Future preparation strategies - What these four developments collectively signal about where field standards are heading and how providers can prepare for increased scrutiny Episode 56 show notes: 00:06 Episode Introduction 01:28 Matthew Perry Case: The Final Sentence 03:47 France Authorizes IV Ketamine for Suicidal Crisis 07:03 Texas Medical Board Update: PKT Rules Still Pending 08:37 Trump Executive Order: Federal Fast-Track for Psychedelic Therapy 10:43 The REMS Advantage: What Regulatory-Ready Looks Like 12:34 Final Thoughts Thanks for listening Selected Links From the Episode: 📖Prefer to read? Check out our related blog post: Ketamine Therapy Regulations Spring 2026: Perry Sentencing, Texas Rules, France Authorization, and Federal Policy Shifts [https://www.ketaminestartup.com/blog/ketamine-regulations-spring-2026-perry-texas-france-federal] 🎧Listen to the full story about what’s about to happen in Texas: Episode 049 - Texas Medical Board Proposes Comprehensive Ketamine Therapy Regulations - What It Means for the Industry [https://www.ketaminestartup.com/podcast/episode-049] 📋Episode references and sources [http://www.ketaminestartup.com/blog/ketamine-regulations-spring-2026-perry-texas-france-federal#ref] 📝 Complete show notes with resources and links, please visit https://www.ketaminestartup.com/podcast/episode-056 [https://www.ketaminestartup.com/podcast/episode-056] Follow us on Linkedin [https://www.linkedin.com/company/ketamine-startup] Ketamine StartUp Website [https://www.ketaminestartup.com] YouTube [https://www.youtube.com/@ketaminestartup] 🚀Want to fast track launching your ketamine clinic? If so, download our free checklist [http://www.ketaminestartup.com/checklist].

Episode 55 - Career Reinvention Success: Why Going Backwards Made Dr. Ruchir Gupta Advance

In this conversation, Dr. Ruchir Gupta shares his unconventional journey from established anesthesiologist to successful pain medicine entrepreneur. After 10 years of practicing anesthesia, he made the bold decision to return for a pain fellowship at Mayo Clinic, where he was older than most of his attendings. Dr. Gupta's story shows how strategic career reinvention can create competitive advantages in medicine. By combining his decade of anesthesia experience with pain medicine fellowship training, he identified a market opportunity that others overlooked: IV ketamine therapy for chronic pain patients. While other pain physicians were hesitant to offer ketamine infusions due to unfamiliarity with anesthetic protocols, Dr. Gupta's background made him uniquely qualified to bridge this gap. You'll hear about how his specialized fibromyalgia protocols achieves 80% success rates, his insights about monitoring standards including the "fifth vital sign" of proper patient follow up, and practical business advice about overcoming analysis paralysis. Dr. Gupta's journey from zero to building Mountain View Headache and Spine Institute offers valuable lessons for any medical professional considering practice ownership or career reinvention. His approach challenges common physician assumptions about entrepreneurship and shows how leveraging existing skills can lead to practice success. What You'll Learn in This Episode · Career reinvention strategy: how Dr. Gupta leveraged his anesthesia background to differentiate his pain practice and why returning to fellowship training became a competitive advantage rather than a setback · Physician entrepreneurship barriers: why medical professionals create mental obstacles around private practice that dentists, chiropractors, and other healthcare providers don't experience, and how to overcome this mindset · Clinical monitoring standards: detailed recommendations for ketamine infusion monitoring, including the importance of continuous EKG, pulse oximetry, and blood pressure monitoring for longer pain protocols · The "fifth vital sign" concept: why proper patient follow up and outcome measurement are essential for maintaining medical credibility and avoiding the "med spa" trap in ketamine therapy · Business development approach: practical strategies for practice growth including LinkedIn networking, physician education sessions, and building referral relationships with skeptical providers · Cross-disciplinary medicine benefits: why Dr. Gupta believes future physicians should combine multiple specialties or degrees to offer integrated approaches and differentiated services · Pain and mood disorder integration: clinical insights about treating patients with concurrent chronic pain and depression, including combination Spravato and ketamine protocols 📋 Professional Education Disclaimer: Content for licensed healthcare providers for educational purposes only. Does not constitute medical, legal, or business advice. Always consult qualified professionals for specific clinical and practice decisions. Key Takeaways · Reinvention requires strategic thinking, not just courage. Dr. Gupta's success came from identifying how his anesthesia background created competitive advantages in pain medicine, particularly with ketamine therapy that other providers avoided. · Physician mindset creates artificial entrepreneurship barriers. Unlike dentists and chiropractors who routinely start private practices, physicians have developed cultural resistance to entrepreneurship that isn't based on actual capability or market realities. · Clinical differentiation drives practice success. By offering IV ketamine when other pain doctors wouldn't, Dr. Gupta created a unique market position that generated demand for both ketamine services and traditional pain procedures. · Fibromyalgia responds differently than other conditions. His 80% success rate comes from recognizing that fibromyalgia requires different protocols than CRPS or depression, using shorter duration but potentially higher dose infusions. · Safety standards must match treatment complexity. Longer pain infusions require more comprehensive monitoring than depression protocols, including but not limited to continuous EKG and regular blood pressure checks every 15 minutes. · The "fifth vital sign" prevents med spa perception. Proper patient follow up with objective outcome measures maintains medical credibility and guides treatment decisions. · Cross-training creates competitive advantages. Combining anesthesia experience with pain medicine training allowed Dr. Gupta to offer services that single-specialty providers couldn't safely provide. · Business planning overcomes analysis paralysis. The hardest step is going from zero to one. Once you start a business plan, even imperfectly, the momentum builds and subsequent decisions become easier. · Multiple marketing channels compound results. Success came from combining LinkedIn professional networking, direct physician outreach, literature sharing, and educational presentations rather than relying on single strategies. Episode 55 show notes: 00:00:00 - Teaser: The Physician Mindset Problem 00:00:31 - Episode Introduction 00:02:14 - Dr. Gupta's Background 00:02:34 - Education: From Political Science to Choosing Anesthesia 00:06:14 - The Decision to Pursue Pain Fellowship 00:08:23 - Fellowship Experience: Being Older Than Attendings 00:09:51 - Turning Setback into Asset: The Ketamine Opportunity 00:13:21 - Starting Mountain View Headache and Spine 00:16:59 - The Physician Entrepreneurship Mindset Problem 00:21:37 - Building Referral Relationships and Practice Growth 00:25:18 - Pain Fellowship Training: What's Missing 00:29:35 - Fibromyalgia Protocols and Success Rates 00:34:27 - Pain vs Mood Disorder Treatment Approaches 00:36:17 - The "Fifth Vital Sign" and Medical Standards 00:40:45 - Monitoring Standards and Safety Considerations 00:50:06 - Business Planning: From Zero to One 00:54:17 - Marketing Strategies That Actually Work 00:56:05 - Rapid Fire Questions: What's on Your Desk 00:57:42 - Relaxation and Pickleball with His Son 00:58:04 - Hidden Talent: Writing Historical Fiction 00:59:22 - Time Travel: Ancient Rome 01:01:04 - Alternative Career: Finance and Building Businesses 01:01:28 - Contact Information 01:02:04 - Final Thoughts and Show Resources Thanks for listening 📝 Complete show notes with resources and links, please visit https://www.ketaminestartup.com/podcast/episode-055 [https://www.ketaminestartup.com/podcast/episode-055] Follow us on Linkedin [https://www.linkedin.com/company/ketamine-startup] Ketamine StartUp Website [https://www.ketaminestartup.com] YouTube [https://www.youtube.com/@ketaminestartup] 🚀Want to fast track launching your ketamine clinic? If so, download our free checklist [http://www.ketaminestartup.com/checklist].

Episode 54 -The Public Perception Reality Check: Psychedelic Culture and Ketamine Therapy with Shane Mauss

🚨 Content Warning: This episode contains discussions about mental health challenges including suicidal ideation, psychedelic substances from cultural and therapeutic perspectives, and occasional strong language. Listener discretion is advised, as some content may not be suitable for all audiences. Please prioritize your well-being while listening. If you or someone you know is struggling with mental health challenges, the 988 Suicide & Crisis Lifeline provides free, confidential support 24/7. Call or text 9-8-8 to connect with trained crisis counselors. In this unique episode, we step outside our usual clinical focus to gain a cultural insider's perspective on how psychedelic therapy is perceived in the broader public consciousness. Comedian Shane Mauss brings an invaluable viewpoint as someone who has been immersed in psychedelic culture since 2016, touring extensively and observing how public attitudes have evolved around these treatments. Shane offers a cultural timeline of how psychedelic perception shifted from 2004 when even mentioning mushrooms on stage was taboo, through the Michael Pollan watershed moment in 2017, to today's complex landscape where ketamine therapy exists alongside telehealth services, recreational use, and the lingering effects of celebrity deaths on public perception. Drawing from his years of cultural immersion and personal experience, he provides insights that help clinicians understand the broader context their patients are navigating. This conversation covers the cultural challenges ketamine providers face in a world where recreational and therapeutic ketamine coexist, where anesthesiologists are questioned about their legitimacy in the therapy space, and where the Matthew Perry tragedy continues to influence public perception. Shane shares his personal ketamine treatment experience and explains his perspective on why ketamine serves as the best "first psychedelic experience" for most people. Perhaps most valuable for providers, Shane offers crucial insights about maintaining scientific rigor in an industry increasingly influenced by wellness culture hype, emphasizing the critical difference between evidence-based practitioners who hedge their bets and wellness influencers who make unfounded claims. What You'll Learn in This Episode · Cultural evolution timeline - Shane's firsthand observations of how psychedelic perception shifted from 2004 taboo through Michael Pollan's 2017 cultural impact to today's medicalization era · Public perception landscape - The complex cultural context your patients navigate, from recreational associations to celebrity death fears to wellness industry hype · Recreational vs clinical disconnect - How street users avoiding K-holes while clinicians may seek deep therapeutic experiences can create public confusion about treatment goals · Shane's personal ketamine journey - His first clinical session and why it surprised him after 21 years of psychedelic experience · Industry disruption insights - How telehealth ketamine services changed the landscape around 2022-2023 and created new competitive dynamics · Celebrity death impact analysis - Shane's perspective on how the Matthew Perry tragedy creates disproportionate fear around statistically safe treatments · Science vs wellness culture - The crucial distinction between evidence-based practitioners and influencers, and why scientific humility builds long-term trust · Rapid intervention advantages - How ketamine's acute treatment capability makes it valuable for interrupting emerging mental health episodes · Evolutionary psychology perspectives - Shane's exploration of why modern isolation amplifies ancestral mental health mechanisms and creates therapeutic opportunities Episode 54 Show Notes 00:00:00 - Teaser: Science vs Wellness Hype 00:00:40 - Introduction and Content Warning 00:02:27 - Shane's Background and Comedy Journey 00:05:30 - The Evolution of Standup Comedy 00:08:00 - Psychedelic Culture Timeline: 2004-2026 00:13:00 - Michael Pollan's Cultural Impact 00:18:00 - Current Public Perception of Ketamine Therapy 00:24:22 - Shane's Personal Ketamine Experience 00:35:06 - Ketamine vs Classical Psychedelics 00:38:00 - Default Mode Network and Suicidal Ideation 00:46:33 - Evolution of Depression and Modern Society 00:54:32 - Advice for Clinicians: Education and Ethics 01:02:24 - Rapid Fire Questions 01:09:30 - Evolutionary Purpose of Altered States 01:14:30 - Shane's Projects and Where to Find Him 01:20:14 - Episode Wrap-up and Resources Thanks for listening Connect With Shane Mauss: · Shane’s Website [https://www.shanemauss.com/] - check for a live show near you! · Here We Are Podcast [https://www.herewearepodcast.com/] · Instagram [https://www.instagram.com/shane_mauss] · Youtube [https://www.youtube.com/channel/UC-OicGAn4ZB0LCcNH89yRPQ] Trips Comedy Specials: · First Dose (Full Comedy Special) [https://www.youtube.com/watch?v=dHh3OSbTcWM] · Second part of Trips 4/19 Youtube May 19th 📝 Complete show notes with resources and links, please visit www.ketaminestartup.com/episode-54 [http://www.ketaminestartup.com/episode-54] Follow us on LinkedIn [https://www.linkedin.com/company/ketamine-startup] Ketamine StartUp Website [https://www.ketaminestartup.com] YouTube [https://www.youtube.com/@ketaminestartup] 🚀Want to fast track launching your ketamine clinic? If so, download our free checklist [http://www.ketaminestartup.com/checklist].

Episode 53 - The Collective Lie in Ketamine Therapy (Part 2): MSKIT Protocol and the Future of Ketamine Therapy

In Part 2 of our conversation with Charles Miller from Scenic City Neurotherapy, we get into the practical side of his controversial "collective lie" thesis from Part 1. Charles walks through his MSKIT (Minimally Stimulated Ketamine Infusion Therapy) approach, explaining when he believes therapeutic integration should actually happen: weeks after treatment during the neuroplasticity window, not during altered states. He addresses how he manages patient expectations around epiphanies and insights, arguing these are retrospective brain noise rather than therapeutic mechanisms. You'll hear Charles use memorable analogies—from cheese obsessions to rollercoaster highs—to explain why he believes the psychedelic experience itself isn't doing the heavy lifting. He makes the case that ketamine is upgrading synaptic function, not providing mystical cures, and that the real work happens when patients are sober and doing therapy afterward. Through detailed audio sidebars, we explore the crucial relationship between BDNF and sleep (and why post-treatment rest matters more than most clinics acknowledge), and examine the metabolite pathway that creates ketamine's addiction potential. Charles also shares his vision for the future of ketamine therapy, advocating for greater scientific rigor and proper medical oversight while critiquing the growing trend of unqualified providers administering ketamine. If you're questioning whether the approaches many of us have been using actually serve our patients best, this conversation will give you a lot to think about. What You'll Learn in This Episode · Patient education strategies - How to remove performance pressure by explaining "you can't make this work better or worse" and framing treatment as physiology, not psychology · Managing epiphanies and insights - Charles's perspective on why experiences are retrospective brain noise rather than therapeutic mechanisms, and how to validate without overemphasizing · BDNF and sleep optimization - The critical relationship between post-treatment sleep quality and neuroplasticity consolidation that many clinics overlook · Ketamine's addiction pathway - Understanding the hydroxynorketamine metabolite mechanism and why "more is not better" with dosing protocols · Pain protocol applications - How he incorporates NAD, lidocaine, magnesium, and anti-inflammatories for comprehensive chronic pain treatment · Future field vision - Charles's call for greater scientific rigor, proper medical oversight, and evidence-based protocols over speculative experiential approaches Key Takeaways · Therapeutic integration may be more effective up to weeks after ketamine treatment when the neuroplasticity window is active, rather than during altered states when processing capacity is diminished · Patient education could focus on removing performance pressure by explaining ketamine as physiological process rather than psychological work, helping patients understand "you can't mess this up" · Ketamine experiences might be retrospective rather than revelatory, reflecting existing knowledge without noise rather than generating new insights, which suggests focusing on post-treatment integration work · Sleep quality in days following ketamine treatment could significantly impact neuroplasticity consolidation, as BDNF release during rest helps lock in synaptic changes initiated by treatment · Ketamine's addiction potential may stem from the hydroxynorketamine metabolite binding to opioid receptors at high doses, supporting protocols that emphasize "more is not better" dosing approaches · Mental health symptoms might represent accurate emotional responses to synaptic dysfunction rather than diseases themselves, with ketamine enhancing processing speed and accuracy rather than changing brain content · Providers could benefit from understanding ketamine's "dirty drug" pharmacology, including sodium channel blocking effects that contribute to dissociation and can be addressed with targeted adjuncts like lidocaine Episode 53 show notes: 00:00:00 - Teaser: This Is Not Magic, This Is Science 00:00:17 - Introduction and Part 2 Setup 00:01:54 - When Therapy Should Actually Happen: Physical Therapy Doesn't Occur During Surgery 00:02:48 - Optimal Timing for Therapeutic Integration: The Weeks That Follow Treatment 00:05:31 - The Science Behind Post-Treatment Rest: BDNF Release and Sleep 00:07:25 - Audio Sidebar: BDNF and Sleep Connection 00:09:29 - Managing Patient Epiphanies: The Cheese Story and Brain Noise 00:13:30 - Mental Health as Synaptic Processing Speed 00:16:45 - Why Experience-Driven Treatment Would Require Daily Ketamine 00:18:04 - MSKIT Protocol: Minimally Stimulated Ketamine Infusion Therapy 00:22:12 - Minimally Stimulating Environment: Binaural Beats and Brain Noise 00:25:30 - Pain Protocols and the "Dirty Drug" Concept 00:26:57 - Audio Sidebar: Ketamine's Metabolite Addiction Pathway 00:30:31 - Future Vision: Greater Rigor and Medical Oversight 00:34:56 - Rapid Fire Personal Questions 00:42:55 - Final Thoughts and Episode Wrap-up Thanks for listening 📋 Professional Education Disclaimer: Content for licensed healthcare providers for educational purposes only. Does not constitute medical, legal, or business advice. Always consult qualified professionals for specific clinical and practice decisions. Connect with Charles Miller & Scenic City Neurotherapy: Website [https://sceniccityneurotherapy.com/] Instagram [https://www.instagram.com/sceniccityneuro/] LinkedIn [https://www.linkedin.com/company/scenic-city-neurotherapy-ketamine-tms/] 📝 Complete show notes with resources and  links, please visit www.ketaminestartup.com/podcast/episode-053 [http://www.ketaminestartup.com/podcast/episode-053] Follow us on LinkedIn [https://www.linkedin.com/company/ketamine-startup] Ketamine StartUp Website [https://www.ketaminestartup.com] YouTube [https://www.youtube.com/@ketaminestartup] 🚀Want to fast track launching your ketamine clinic? If so, download our free checklist [http://www.ketaminestartup.com/checklist].